Search results for: Maria Lowe
Filter search results
The Doctor’s (Ethical and Economic) Dilemma
1 August 1996
…is not cost cutting — applying ‘the most efficacious interventions to maximise the quality and quantity of life for individual patients’ may ‘raise rather than lower’ the cost of their…
The Future of Primary Care
1 January 1996
…its population but is also associated with lower costs. It is therefore concluded that strong primary care is an efficient use of health care resources. We need to put the…
The Trajectory of Dementia in the UK – Making a Difference
1 June 2014
…by one third (666,000) and reduce the need for informal carers by 566,000; costs of care would be £21 billion lower in 2050 — £38 billion rather than £59 billion….
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
…biosimilars to third party payers in these two areas will be lower than originally thought. The biosimilar regulations in the US are not complete, and a number of issues are…
Age and Utilities: Issues for HTA
1 April 2017
…oldest respondents are systematically (and significantly, for the majority of profiles) lower than those obtained from younger age groups. Our study also finds that significant differences in values amongst age…
Transferability of HTA
4 January 2017
…transfer possible, and how decisions can be adapted to different contexts. Overall, we conclude that some of the barriers to transferability may be lower than is generally believed. The background…
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
…explore potential for in-class competition for DAAs to offset innovators’ market power and to maximise the social welfare generated by the adoption of pharmaceutical innovation via lower prices. Using a…
The Future of Global Health Procurement: Issues around Pricing Transparency
1 March 2019
…medicines. The paper concludes that transparency of the procurement processes significantly lowers costs by encouraging bidders. The authors do not recommend price transparency for on-patent medicines as the effect will…
Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead
1 January 2020
…adult perspective (considering their own health) and EQ-5D-Y health states from a child perspective (considering the health of a 10-year-old child). Overall, respondents gave lower values under the adult perspective…